Medical management of Cushing's disease

Journal of Neuro-Oncology

Volumn 117, Issue 3, 2014, Pages 407-414

  Tritos, Nicholas A ^a,b   Biller, Beverly M K ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cushing's disease; Cushing's syndrome; Medical therapy; Pituitary adenoma

Indexed keywords

BEXAROTENE; CABERGOLINE; CORTICOTROPIN; ETOMIDATE; KETOCONAZOLE; LAPATINIB; METYRAPONE; MIFEPRISTONE; MITOTANE; PASIREOTIDE;

COMBINATION CHEMOTHERAPY; CORTICOTROPIN RELEASE; CUSHING DISEASE; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HUMAN; HYPERCORTISOLISM; PATHOGENESIS; PATIENT SELECTION; PITUITARY ADENOMECTOMY; PREOPERATIVE CARE; REVIEW; TRANSSPHENOIDAL HYPOPHYSECTOMY; PITUITARY ACTH HYPERSECRETION;

HUMANS; PITUITARY ACTH HYPERSECRETION;

EID: 84901271753     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1269-1     Document Type: Review

References (50)

1. Cushing H (1932) The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp 50:137-195
2. Newell-Price J, Bertagna X, Grossman AB, Nieman LK (2006) Cushing's syndrome. Lancet 367(9522):1605-1617 (Pubitemid 43674231)
3. Tritos NA, Biller BM, Swearingen B (2011) Management of Cushing disease. Nat Rev Endocrinol 7(5):279-289
4. Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M (2008) Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 93(7):2454-2462 (Pubitemid 352008503)
5. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM (2008) The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93(5):1526-1540 (Pubitemid 351656485)
6. Barker FG 2nd, Klibanski A, Swearingen B (2003) Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab 88(10):4709-4719 (Pubitemid 37357516)
7. Swearingen B, Biller BM, Barker FG 2nd, Katznelson L, Grinspoon S, Klibanski A, Zervas NT (1999) Long-term mortality after transsphenoidal surgery for Cushing disease. Ann Intern Med 130(10):821-824 (Pubitemid 29231150)
8. Blevins LS Jr, Christy JH, Khajavi M, Tindall GT (1998) Outcomes of therapy for Cushing's disease due to adrenocorticotropin-secreting pituitary macroadenomas. J Clin Endocrinol Metab 83(1):63-67 (Pubitemid 28498311)
9. Bochicchio D, Losa M, Buchfelder M (1995) Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery: a retrospective study by the European Cushing's Disease Survey Group. J Clin Endocrinol Metab 80(11):3114-3120
10. Rees DA, Hanna FW, Davies JS, Mills RG, Vafidis J, Scanlon MF (2002) Long-term follow-up results of transsphenoidal surgery for Cushing's disease in a single centre using strict criteria for remission. Clin Endocrinol (Oxf) 56(4):541-551 (Pubitemid 34429630)
11. Shimon I, Ram Z, Cohen ZR, Hadani M (2002) Transsphenoidal surgery for Cushing's disease: endocrinological follow-up monitoring of 82 patients. Neurosurgery 51(1):57-61 (discussion 61-52)
12. Patil CG, Prevedello DM, Lad SP, Vance ML, Thorner MO, Katznelson L, Laws ER Jr (2008) Late recurrences of Cushing's disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab 93(2):358-362 (Pubitemid 351246675)
13. Sonino N, Zielezny M, Fava GA, Fallo F, Boscaro M (1996) Risk factors and long-term outcome in pituitary-dependent Cushing's disease. J Clin Endocrinol Metab 81(7):2647-2652 (Pubitemid 26240292)
14. Chen JC, Amar AP, Choi S, Singer P, Couldwell WT, Weiss MH (2003) Transsphenoidal microsurgical treatment of Cushing disease: postoperative assessment of surgical efficacy by application of an overnight low-dose dexamethasone suppression test. J Neurosurg 98(5):967-973 (Pubitemid 36460886)
15. Estrada J, Garcia-Uria J, Lamas C, Alfaro J, Lucas T, Diez S, Salto L, Barcelo B (2001) The complete normalization of the adrenocortical function as the criterion of cure after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab 86(12):5695-5699 (Pubitemid 33152610)
16. Trainer PJ, Lawrie HS, Verhelst J, Howlett TA, Lowe DG, Grossman AB, Savage MO, Afshar F, Besser GM (1993) Transsphenoidal resection in Cushing's disease: undetectable serum cortisol as the definition of successful treatment. Clin Endocrinol (Oxf) 38(1):73-78 (Pubitemid 23030276)
17. Bertagna X, Guignat L (2013) Approach to the Cushing's disease patient with persistent/recurrent hypercortisolism after pituitary surgery. J Clin Endocrinol Metab 98(4):1307-1318
18. Liubinas SV, Porto LD, Kaye AH (2011) Management of recurrent Cushing's disease. J Clin Neurosci 18(1):7-12
19. Estrada J, Boronat M, Mielgo M, Magallon R, Millan I, Diez S, Lucas T, Barcelo B (1997) The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. N Engl J Med 336(3):172-177 (Pubitemid 27034962)
20. Petit JH, Biller BM, Yock TI, Swearingen B, Coen JJ, Chapman P, Ancukiewicz M, Bussiere M, Klibanski A, Loeffler JS (2008) Proton stereotactic radiotherapy for persistent adrenocorticotropin-producing adenomas. J Clin Endocrinol Metab 93(2):393-399 (Pubitemid 351246676)
21. Vella A, Thompson GB, Grant CS, van Heerden JA, Farley DR, Young WF Jr (2001) Laparoscopic adrenalectomy for adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 86(4):1596-1599 (Pubitemid 32374909)
22. Nelson DH, Meakin JW, Dealy JB Jr, Matson DD, Emerson K Jr, Thorn GW (1958) ACTH-producing tumor of the pituitary gland. N Engl J Med 259(4):161-164
23. Tritos NA, Schaefer PW, Stein TD (2011) Case records of the Massachusetts General Hospital. Case 40-2011. A 52-year-old man with weakness, infections, and enlarged adrenal glands. N Engl J Med 365(26):2520-2530
24. Assie G, Bahurel H, Coste J, Silvera S, Kujas M, Dugue MA, Karray F, Dousset B, Bertherat J, Legmann P, Bertagna X (2007) Corticotroph tumor progression after adrenalectomy in Cushing's disease: a reappraisal of Nelson's syndrome. J Clin Endocrinol Metab 92(1):172-179 (Pubitemid 46067527)
25. Chow JT, Thompson GB, Grant CS, Farley DR, Richards ML, Young WF Jr (2008) Bilateral laparoscopic adrenalectomy for corticotrophin-dependent Cushing's syndrome: a review of the Mayo clinic experience. Clin Endocrinol (Oxf) 68(4):513-519 (Pubitemid 351388707)
26. Tritos NA, Biller BM (2012) Advances in medical therapies for Cushing's syndrome. Discov Med 13(69):171-179
27. Findling JW, Raff H (2006) Cushing's syndrome: important issues in diagnosis and management. J Clin Endocrinol Metab 91(10):3746-3753 (Pubitemid 44536836)
28. Klibanski A (2010) Clinical practice prolactinomas. N Engl J Med 362(13):1219-1226
29. de Bruin C, Feelders RA, Lamberts SW, Hofland LJ (2009) Somatostatin and dopamine receptors as targets for medical treatment of Cushing's syndrome. Rev Endocr Metab Disord 10(2):91-102
30. Pivonello R, De Martino MC, Cappabianca P, De Leo M, Faggiano A, Lombardi G, Hofland LJ, Lamberts SW, Colao A (2009) The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 94(1):223-230
31. Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A (2010) Cabergoline monotherapy in the long-term treatment of Cushing's disease. Eur J Endocrinol 163(5):709-716
32. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356(1):29-38 (Pubitemid 46041751)
33. Valassi E, Klibanski A, Biller BM (2010) Clinical review: potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab 95(3):1025-1033
34. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356(1):39-46 (Pubitemid 46041752)
35. Nieman LK (2013) Update in the medical therapy of Cushing's disease. Curr Opin Endocrinol Diabetes Obes 20(4):330-334
36. Ben-Shlomo A, Schmid H, Wawrowsky K, Pichurin O, Hubina E, Chesnokova V, Liu NA, Culler M, Melmed S (2009) Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. J Clin Endocrinol Metab 94(11):4342-4350
37. Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BM, Findling J, Melmed S, Darby CH, Hu K, Wang Y, Freda PU, Grossman AB, Frohman LA, Bertherat J (2009) Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 94(1):115-122
38. Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM (2012) A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med 366(10):914-924
39. Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S (2013) Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab. doi:10.1210/jc.2013-1771
40. Engelhardt D, Weber MM (1994) Therapy of Cushing's syndrome with steroid biosynthesis inhibitors. J Steroid Biochem Mol Biol 49(4-6):261-267 (Pubitemid 24240610)
41. McCance DR, Ritchie CM, Sheridan B, Atkinson AB (1987) Acute hypoadrenalism and hepatotoxicity after treatment with ketoconazole. Lancet 1(8532):573 (Pubitemid 17020775)
42. Verhelst JA, Trainer PJ, Howlett TA, Perry L, Rees LH, Grossman AB, Wass JA, Besser GM (1991) Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol (Oxf) 35(2):169-178
43. Luton JP, Mahoudeau JA, Bouchard P, Thieblot P, Hautecouverture M, Simon D, Laudat MH, Touitou Y, Bricaire H (1979) Treatment of Cushing's disease by O, p'DDD. Survey of 62 cases. N Engl J Med 300(9):459-464 (Pubitemid 9134790)
44. Baudry C, Coste J, Bou Khalil R, Silvera S, Guignat L, Guibourdenche J, Abbas H, Legmann P, Bertagna X, Bertherat J (2012) Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center. Eur J Endocrinol 167(4):473-481
45. Kamenicky P, Droumaguet C, Salenave S, Blanchard A, Jublanc C, Gautier JF, Brailly-Tabard S, Leboulleux S, Schlumberger M, Baudin E, Chanson P, Young J (2011) Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab 96(9):2796-2804
46. Schulte HM, Benker G, Reinwein D, Sippell WG, Allolio B (1990) Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab 70(5):1426-1430
47. Fleseriu M, Molitch ME, Gross C, Schteingart DE, Vaughan TB, Biller BM (2013) A new therapeutic approach in the medical treatment of Cushing's syndrome: glucocorticoid receptor blockade with Mifepristone. Endocr Pract 19(2):313-326
48. Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C (2012) Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab 97(6):2039-2049
49. Feelders RA, de Bruin C, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, Zelissen PM, van Heerebeek R, de Jong FH, van der Lely AJ, de Herder WW, Hofland LJ, Lamberts SW (2010) Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. N Engl J Med 362(19):1846-1848
50. Vilar L, Naves LA, Azevedo MF, Arruda MJ, Arahata CM, Moura ESL, Agra R, Pontes L, Montenegro L, Albuquerque JL, Canadas V (2010) Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease. Pituitary 13(2):123-129